Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:NKTR
  • CUSIP: 64026810
  • Web:
  • Market Cap: $3.59 billion
  • Outstanding Shares: 155,149,000
Average Prices:
  • 50 Day Moving Avg: $19.78
  • 200 Day Moving Avg: $17.64
  • 52 Week Range: $11.41 - $24.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.45
  • P/E Growth: 2.69
Sales & Book Value:
  • Annual Revenue: $131.28 million
  • Price / Sales: 27.32
  • Book Value: $0.29 per share
  • Price / Book: 79.72
  • EBIDTA: ($142,140,000.00)
  • Net Margins: -150.74%
  • Return on Equity: -3,072.86%
  • Return on Assets: -39.87%
  • Debt-to-Equity Ratio: 5.49%
  • Current Ratio: 4.85%
  • Quick Ratio: 4.69%
  • Average Volume: 1.31 million shs.
  • Beta: 1.48
  • Short Ratio: 9.43
Frequently Asked Questions for Nektar Therapeutics (NASDAQ:NKTR)

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02. The firm earned $24.73 million during the quarter, compared to analysts' expectations of $29.43 million. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The firm's revenue for the quarter was down 58.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.14) EPS. View Nektar Therapeutics' Earnings History.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?

8 equities research analysts have issued 1-year price targets for Nektar Therapeutics' shares. Their forecasts range from $23.00 to $31.00. On average, they anticipate Nektar Therapeutics' share price to reach $26.29 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.

What are analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. According to Zacks Investment Research, "Nektar reported wider than expected loss in fourth quarter 2016 with revenue missing estimates. The launches of its drugs Movantik and Adynovate have been on track with both the products performing impressively. Moreover, partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which will boost its financial position significantly. Nektar also has a deep and promising pipeline, with several updates lined up for the next several quarters. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, and disappointing products sales could have a significant impact on its financial results. The company’s shares outperformed the Zacks classified Medical-Drugs industry in the year so far." (3/27/2017)
  • 2. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 3. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
  • 4. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

  • Robert B. Chess, Independent Chairman of the Board
  • Howard W. Robin, President, Chief Executive Officer, Director
  • Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President
  • John L. Nicholson, Chief Operating Officer, Senior Vice President
  • Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer
  • Stephen K. Doberstein Ph.D., Senior Vice President, Chief Scientific Officer
  • Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer
  • Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations
  • R. Scott Greer, Independent Director
  • Joseph J. Krivulka, Independent Director

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Harvey Capital Management Inc. (0.19%), Russell Investments Group Ltd. (0.09%), US Bancorp DE (0.06%), Louisiana State Employees Retirement System (0.04%), Rothschild Capital Partners LLC (0.04%) and Franklin Street Advisors Inc. NC (0.04%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Stephen K Doberstein and Susan Wang. View Institutional Ownership Trends for Nektar Therapeutics.

Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Capstone Asset Management Co., Shell Asset Management Co. and Bank of Montreal Can. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Capital Partners LLC, Russell Investments Group Ltd., State of Alaska Department of Revenue, Aperio Group LLC, Harvey Capital Management Inc., Municipal Employees Retirement System of Michigan, LS Investment Advisors LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $23.12.

MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.29 (13.69% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Jefferies Group LLCReiterated RatingBuy$23.00MediumView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/22/2017Roth CapitalSet Price TargetBuy$31.00MediumView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
3/21/2017J P Morgan Chase & CoSet Price TargetBuy$24.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Earnings History by Quarter for Nektar Therapeutics (NASDAQ NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.31)($0.40)
Q2 20172($0.37)($0.29)($0.33)
Q3 20172($0.35)($0.29)($0.32)
Q4 20173($0.33)$0.08($0.14)
Q1 20182($0.35)($0.12)($0.24)
Q2 20182($0.36)($0.13)($0.25)
Q3 20182($0.36)($0.13)($0.25)
Q4 20181($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 5.44%
Institutional Ownership Percentage: 93.85%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.00View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.00View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.40View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.56View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.55View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.00View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.00View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.98View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Nektar Therapeutics (NASDAQ:NKTR)
Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline logoNektar Makes A Stride Forward In Resolving Autoimmune Diseases - Seeking Alpha - July 26 at 4:52 AM logoEli Lilly CEO: Strong quarter driven by new products - July 26 at 4:51 AM logoNektar teams up with Lilly to develop autoimmune candidate NKTR-358 - July 25 at 6:11 AM logoLilly (LLY), Nektar Therapeutics (NKTR) Announce Pact to Develop and Commercialize NKTR-358 - July 25 at 6:11 AM logoBiotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - July 25 at 6:11 AM logoLilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune ... - PR Newswire (press release) - July 24 at 7:49 AM logoLilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy - July 24 at 7:49 AM logoEMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug - July 22 at 6:56 AM logoNektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from Jefferies Group LLC - July 21 at 1:44 PM logoNektar Therapeutics (NASDAQ:NKTR) SVP Sells $1,158,812.00 in Stock - July 20 at 7:45 PM logoNektar Therapeutics (NKTR): Data Confirms Likeability Differentiation vs Oxycontin - Jefferies - - July 20 at 2:27 AM logoNektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational ... - PR Newswire (press release) - July 20 at 2:27 AM logoPuma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise - - July 19 at 5:19 AM logoNektar Therapeutics (NKTR) Reports Topline Data from Human Abuse Potential Study for NKTR-181 to Treat Chronic ... - - July 19 at 5:19 AM logoNektar Therapeutics (NKTR) Reports Topline Data from Human Abuse Potential Study for NKTR-181 to Treat Chronic Pain - July 19 at 12:16 AM logoNektar Therapeutics (NKTR) Updates On Topline Results of Oral Human Abuse Potential (NKTR-181) - Slideshow - July 19 at 12:16 AM logoNektar Shares Boosted by Promising Results on Opioid Addiction Study - July 19 at 12:16 AM logoNektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain - July 19 at 12:16 AM logoPuma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise - July 19 at 12:16 AM logoInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells 30,000 Shares of Stock - July 18 at 10:28 PM logoIvan P. Gergel Sells 8,389 Shares of Nektar Therapeutics (NKTR) Stock - July 14 at 8:24 PM logoIvan P. Gergel Sells 45,080 Shares of Nektar Therapeutics (NKTR) Stock - July 13 at 10:52 PM logoNektar Therapeutics (NKTR) Receives Average Recommendation of "Buy" from Brokerages - July 11 at 7:52 AM logoNektar Therapeutics (NKTR) Presents New Preclinical Data for NKTR-358 - July 11 at 5:19 AM logoNektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London - July 11 at 5:19 AM logoImplied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options - Nasdaq - July 7 at 7:38 AM logoImplied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options - July 7 at 7:38 AM logo Analysts Anticipate Nektar Therapeutics (NASDAQ:NKTR) Will Announce Quarterly Sales of $36.49 Million - July 1 at 10:04 AM logo-$0.34 EPS Expected for Nektar Therapeutics (NKTR) This Quarter - June 29 at 7:48 AM logoBrokers Set Expectations for Nektar Therapeutics' Q2 2017 Earnings (NKTR) - June 28 at 7:26 AM logoNektar Therapeutics (NKTR) Upgraded to Buy at BidaskClub - June 28 at 12:04 AM logoNektar Therapeutics (NKTR) Rating Reiterated by William Blair - June 26 at 8:34 AM logoNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : June 22, 2017 - June 22 at 8:17 AM logoNektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why - June 16 at 7:47 PM logoNektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why - June 16 at 7:47 PM logoNektar Therapeutics (NKTR) Receives Average Rating of "Buy" from Analysts - June 16 at 10:50 AM logoETFs with exposure to Nektar Therapeutics : June 9, 2017 - June 9 at 7:02 PM logoNektar Therapeutics (NKTR) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 7 at 6:36 PM logo Brokerages Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $36.49 Million - June 7 at 1:06 PM logoNektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City - June 6 at 7:33 PM logoNektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society ... - PR Newswire (press release) - June 6 at 8:58 AM logoBRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214 - June 5 at 7:29 PM logoNektar Therapeutics (NKTR) Analyst & Investor Event at 2017 ASCO Annual Meeting - Slideshow - June 5 at 7:29 PM logoNektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - June 5 at 7:29 PM logo Brokerages Anticipate Nektar Therapeutics (NKTR) Will Post Earnings of -$0.34 Per Share - June 5 at 9:36 AM logoNektar Therapeutics (NKTR) Upgraded at ValuEngine - June 4 at 12:34 AM logoNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : June 2, 2017 - June 2 at 9:11 PM logoAre Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017? - May 30 at 6:31 PM logoRoth Capital Analysts Give Nektar Therapeutics (NKTR) a $31.00 Price Target - May 23 at 9:20 PM logoNektar Therapeutics (NKTR) Presents At UBS Global Healthcare Conference 2017 - Slideshow - May 23 at 6:20 PM



Nektar Therapeutics (NKTR) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff